N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
Hepatitis C Virus
Primary: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Methadone Enantiomers When Administered With or Without Boceprevir — 50.1; 42.4; 56.9; 44.6…
Phase 2 N=154 Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
Constipation
Primary: Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration — 19.2; 31.4; 19.2 percentage of participants — p=0.1790
N/A N=34 Preconditioning for Aneurismal Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
Primary: Number of Patients With Deep Vein Thrombosis for Safety Assessment. — 0; 3; 0; 0 participants
Phase 4 N=43 BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.
HIV
Primary: Maintenance of Virologic Suppression — 13; 14; 10; 0 participants
Phase 2 N=31 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Parkinson's Disease
Primary: Mean Cortical Amyloid Burden — 0.990; 1.051; 1.146 SUVR
Phase 3 N=846 A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 Years — 94.9 percentage of participants
Phase 2 N=71 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Complete Response (CR) — 3 participants
Phase 4 N=178 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
Sustained Virologic Response · IL28B Polymorphism
Primary: Sustained Virologic Response Depending on the Dosage of Peginterferon Alfa 2a — 52; 44 participants who achieved SVR
Phase 3 N=606 Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)
Urethritis
Primary: mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit — 15; 8 participants
Phase 4 N=120 Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol
Esophagogastroduodenoscopy
Primary: Rate of Administration of Propofol 1% Required to Obtain Uniform Sedation During Endoscopy — 310.7; 280.1 mcg/kg/min — p=<0.05
Phase 2 N=40 Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
Type 1 Diabetes
Primary: Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1…
N/A N=433 A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus
Hydrocephalus
Primary: Number of Subjects With Shunt Infections — 14 participants
Phase 1 N=44 Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
Adult Stem Cell Hematopoetic Transplant
Primary: Patients Experiencing at Least 1 Solicited Local and/or Systemic Adverse Event After High Dose (HD) Trivalent Influenza Vaccine (TIV) or Standard Dose (SD) Trivalent…
Phase 2 N=45 Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Low T3 Syndrome
Primary: Free T3 (FT3) Levels — 3.6; 4.5; 3.9; 3.6 pg/ml — p=<0.05